Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inactivated enterovirus 71 vaccine (KMB-17)
- Development stage
- Phase 4
- Lead developer
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The inactivated enterovirus 71 vaccine (KMB-17) is a whole-virion inactivated biologic vaccine developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) for the prevention of hand, foot, and mouth disease (HFMD) in children. The vaccine is derived from the FY-23K-B strain (genotype C4) of Enterovirus 71, which was isolated during a 2008 outbreak in Fuyang, China. The virus is propagated in the KMB-17 human diploid cell line, purified, and inactivated with formalin. Formulated with an aluminum hydroxide adjuvant, the vaccine is administered as a two-dose intramuscular injection series to children aged 6 to 71 months. Clinical trials demonstrated a 97% protective efficacy against EV71-associated HFMD, leading to its licensure by the China Food and Drug Administration in December 2015.
- Brand names
- EntroVac
- Other names
- Inactivated Enterovirus 71 Vaccine (Human Diploid Cell)EV71 vaccine (IMBCAMS)Enterovirus 71 vaccine (KMB-17)
02
Targets
Enterovirus A71 capsid protein
Beyond the preview
Go deeper on Inactivated enterovirus 71 vaccine (KMB-17).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inactivated enterovirus 71 vaccine (KMB-17).